TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03973294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT-measurement
Description: The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EIT-measurement
Description: The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface.
Study: NCT01331291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: Taken orally
Study: NCT02475928

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Study: NCT02184221

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency stimulation
Description: The parameter of DMS: 0.5Hz
Study: NCT00368264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: azathioprine (2 mg/kg) plus four placebo infusions
Study: NCT01284283

Intervention type: DEVICE
Group type: OTHER
Intervention: Scandinavian Total Ankle Replacement System (STAR Ankle)
Description: For total ankle replacement
Study: NCT00264641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: Hyperinsulinaemic induced hypoglycaemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: Hyperinsulinaemic induced hypoglycaemia
Study: NCT01811927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRO-Kinetic Energy Stent
Description: Bare-metal stent
Study: NCT03790527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBM training
Description: participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
Study: NCT01862887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 24 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Tablet, 400 mg, single dose
Study: NCT01862887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, PH-797804 matched placebo, single dose
Study: NCT03801564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Treatment Group (PRP)
Description: EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Treatment Group (HA)
Description: REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
Study: NCT00353405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: Mass media provides messages that support sexual health skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: Mass media provides messages that support sexual health skills.
Study: NCT00441168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: vincristine: 0.4mg IV push on days 1 to 4
Study: NCT04280978

Intervention type: DIAGNOSTIC_TEST
Intervention: ABI ABC
Description: The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes.
Study: NCT01189045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Description: The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
Study: NCT00353405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group received no social skills training and no media mass media messages.
Study: NCT02734810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase Powder for Oral Solution
Description: Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase Powder for Oral Solution
Description: Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
Study: NCT02143908

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lysine supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00476021

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing IUD (Mirena)
Description: levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (Mirena)
Description: levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
Study: NCT01871610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET amyloid binding imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET amyloid binding imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET amyloid binding imaging
Study: NCT04472936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single catheter approach
Description: Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is \>80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional approach
Description: Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
Study: NCT02526407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing
Description: Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group play
Description: Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
Study: NCT02140437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Adding fulvestrant to the standard endocrine therapy, anastrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: standard endocrine therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: standard endocrine therapy
Study: NCT02558790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Threonic Acid Magnesium Salt (L-TAMS)
Study: NCT03642392

Intervention type: OTHER
Intervention: Identification and treatment of early tendinopathy
Description: Participants receive initial guidance about load reduction when tendinopathy
Study: NCT01175733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
Study: NCT02723968

Intervention type: OTHER
Group type: OTHER
Intervention: glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT
Description: At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HGPIV diagnosis test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HOMAR-IR diagnosis test
Study: NCT03772847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginkgolide
Description: ginkgolide plus alteplase
Study: NCT03662984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofibrate 100Mg Tablet
Description: Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: To compare ciprofibrate
Study: NCT00655967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate (Campral)
Description: During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance \>50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
Study: NCT03617783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotin
Description: Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo-OEI
Study: NCT05099250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: In the central nervous system , it has depressant effects, by antagonism at NMDA receptors and through inhibition of release of catecholamines

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: medical solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: medical solution
Study: NCT00128401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01350245

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Started the day before the transplant to prevent graft versus host disease (GVHD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Started the day before the transplant to prevent graft-versus-host disease (GVHD)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Description: One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation.
Study: NCT01189045

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic Exercise Program
Description: The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
Study: NCT03071172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin for Injection
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin for Injection
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study: NCT04358887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric surgery
Description: after flap reflection bone and root end cutting are done with piezoelectric surgical insert

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional bur
Description: after flap reflection bone and root end cutting are done with surgical bur
Study: NCT00817895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sustained released 5-FU and sustained released cisplatin
Description: 600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sustained released 5-FU
Description: 600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: All patients will accept TACE one month after tumor was resected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: All patients will accept TACE one month after tumor was resected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: All patients will accept TACE one month after tumor was resected.
Study: NCT01430481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosehip powder
Description: The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosehip powder
Description: The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rosehip powder
Description: The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
Study: NCT00112502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg orally twice a day continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg orally twice a day continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg orally twice a day continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg orally twice a day continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: 40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: 40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: 40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.
Study: NCT02185079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training to proficiency
Description: Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.